Natera's circulating tumor DNA test, Signatera, has been incorporated as a pre-specified secondary endpoint in the Phase III ARCHER trial assessing radiation therapy in muscle-invasive bladder cancer. Conducted by the National Clinical Trials Network, the study evaluates the potential for treatment de-intensification without compromising efficacy, with Signatera's minimal residual disease detection employed for monitoring tumor response and recurrence prediction. Prior data affirm improved survival correlated with Signatera-positive patients receiving immunotherapy, emphasizing its biomarker utility.